ERYTECH receives Orphan Drug Designation by the FDA for eryaspase in Acute Myeloid Leukemia

ERYTECH announces that its lead product GRASPA®/eryasp1 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of Acute Myeloid Leukemia (AML), an aggressive form of blood cancer.

Menu